The Effect of Prolonged Testosterone Propionate Administration on the Immature and Adult Female Rat

Mazer, Milton; Mazer, Charles

doi:10.1210/endo-24-2-175

Cited by 32 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aron et al (1967 a) showed that TP given on dioestrus 1 of 4-day cycles could slow up the growth of ovarian follicles. When androgens were administered for prolonged periods, complete ovarian atrophy including arrest of follicular growth was the predominant finding (Mazer and Mazer, 1939). In the present study, follicular size did not exceed 480 im following TP from day 4 until the resumption of prooestru& This corresponds to the size reached by follicles on dioestrus 2 in control 4-day cyclic rats (Buffler and Roser, 1974;Chateau et al, 1981;Boehm et al, 1984).…”

Section: Discussionsupporting

confidence: 51%

Testosterone-Induced Oestrous Cycle Blockade in the Rat: No Evidence for Prolactin Involvement

Boehm¹,

Lazarus²,

Aron³

2009

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

The relation between testosterone-induced oestrous cycle disruption and prolactin (Prl) secretion was studied in the female rat. Testosterone propionate (TP) injection on dioestrus 2 (day 0) of 4-day cycles induced cycle interruption for 12 days. A diurnal pattern of Prl secretion was observed from day 1 to day 6 with high levels in the afternoon and low levels in the morning. Cycle interruption also occurred in TP treated females given a dose of bromocriptine (BRC) known to completely block Prl secretion. Impairment of follicular growth resulted from TP treatment and from TP and BRC treatment as well. Until resumption of prooestrous, the follicular size did not exceed that noted during the dioestrous period of the cycle. Despite resumption of follicular growth from day 9 until day 14, ovulation only took place in a small number of animals. These results indicate that the antigonadotropic effects of Prl were not responsible for cycle disruption in our experimental model and that other mechanisms were in itself sufficient for the disruption. This was discussed in the light of previous findings in our laboratory.

show abstract

Section: Discussionsupporting

confidence: 51%

Testosterone-Induced Oestrous Cycle Blockade in the Rat: No Evidence for Prolactin Involvement

Boehm¹,

Lazarus²,

Aron³

2009

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…In the absence of menstruation and the concomitant absence of uterine stimulation by female hormones, Loeser observed a decrease in size of the fibromyomas in all five patients [2]. Despite these favorable results and the ability of physicians, like Loeser, to stratify patients into groups according to diagnostic criteria, the medical profession was “confronted with the problems of therapeutic indications, margin of safety, and optimal dosage” regarding androgen use in women [47,48]. Despite these valid and serious concerns, Mazer and Mazer did not use them as justification for withholding testosterone treatment [47,48].…”

Section: Testosterone Therapy Of Abnormal Uterine Bleedingmentioning

confidence: 99%

Testosterone Therapy in Women with Gynecological and Sexual Disorders: A Triumph of Clinical Endocrinology from 1938 to 2008

Traish

Feeley

Guay

2009

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction Although the term “medicalization” has been used by some to describe contemporary testosterone use in women with sexual disorders and testosterone deficiency syndrome, testosterone therapy for women with various gynecological and sexual disorders has been practiced since the late 1930s. Aim The study aimed to perform a historical review of testosterone use in women with sexual and gynecological disorders. This review is necessary to bridge important knowledge gaps in the clinical use of testosterone in women with sexual health concerns and to provoke new thoughts and understanding of the multidisciplinary role of testosterone in women’s overall health. Methods Review of medical literature on androgen therapy in women was carried out from 1938 through 2008. Results Approximately 70 years ago, clinicians from various disciplines relied on personal experience and clinical observations for outcome assessment of testosterone therapy in women. These early reports on testosterone use in women with sexual medical problems served as a foundation for the development of contemporary approaches and subsequent testosterone treatment regimens. Testosterone use was reported for sexual dysfunction, abnormal uterine bleeding, dysmenorrhea, menopausal symptoms, chronic mastitis and lactation, and benign and malignant tumors of the breast, uterus, and ovaries. Conclusions Health-care professionals engaged in the management of women’s health issues have observed the benefits of androgen therapy throughout much of the 20th century. Despite this clinical use of testosterone in women for more than seven decades, contemporary testosterone therapy in women is hotly debated, misunderstood, and often misrepresented in the medical community.

show abstract

“…Effects from the p' rolonged administration in the female.-In the adult rat the ovaries develop the "wheel cells" observed as a result of hypophysectomy (182), and atrophic changes in the ovary (183) which, with very high doses in young rats, result in lutein cysts and sometimes in ovarian atrophy without luteinization (184). Similar results are observed in mice (185) and guinea pigs (186).…”

Section: Separation Of Androgens and Related Compounds From Urinementioning

confidence: 56%

Hormones

Koch¹

1940

Annu. Rev. Biochem.

View full text Add to dashboard Cite

Because the more definitely biochemical advances in the field of hormones are very nearly limited to those of the steroid type together with the limited space available for reviewing a very extensive litera ture, I have taken advantage of the editors' liberal policy and have limited this review to the biochemistry of the steroid hormones. ESTROGENSDistribution and forms of estrogens.-Although all of the estro gen activity in cow and hog ovaries is considered to be in the free form, only 50 to 75 per cent is free in the horse ovary or its follicular fluid (1). During pregnancy 50 to 75 per cent of the blood estrogens in women are in the free form (2). The best method of hydrolysis of the conjugated forms of estrogens in pregnancy urine is still a prob lem. One g.roup recommends boiling the pregnancy urine for ten minutes with 15 per cent concentrated hydrochloric added. Longer heating results in serious loss of estrogens (3). Others recommend that the urine from pregnant mares be allowed to stand at pH 0.4 to 0.6 at room temperature for at least four weeks (4). The writer, in studies on urine from normal men and nonpregnant women, has obtained the highest yield of estrogens by boiling the urine previously acidified to pH 1 to 1.2 with hydrochloric acid for fifteen minutes.Longer boiling at this pH also causes destruction of estrogens. The gradual increase in the urinary excretion of estrogens in women to a peak of 80,000 rat units near the termination has been confirmed, but in one case of toxemia of pregnancy, the excretion was subnormal.

show abstract

The Effect of Prolonged Testosterone Propionate Administration on the Immature and Adult Female Rat

Cited by 32 publications

References 0 publications

Testosterone-Induced Oestrous Cycle Blockade in the Rat: No Evidence for Prolactin Involvement

Testosterone-Induced Oestrous Cycle Blockade in the Rat: No Evidence for Prolactin Involvement

Testosterone Therapy in Women with Gynecological and Sexual Disorders: A Triumph of Clinical Endocrinology from 1938 to 2008

Hormones

Contact Info

Product

Resources

About